Matthew M. Gubin, Ph.D.
Department of Immunology, Division of Discovery Science
In the News
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX
Member, The University of Texas Graduate School of Biomedical Sciences (GSBS), Houston, TX
Education & Training
Degree-Granting Education
| 2012 | University of Missouri, Columbia, Missouri, US, Ph.D. in Microbiology and Immunology |
| 2004 | University of Missouri, Columbia, Missouri, US, BS in Biological Sciences |
Postgraduate Training
| 2014-2017 | Postdoctoral Fellow, Department of Pathology and Immunology, Laboratory of Robert Schreiber, PhD, Washington University School of Medicine, St. Louis, Missouri |
| 2012-2014 | Cancer Research Institute (CRI) Postdoctoral Fellow, Department of Pathology and Immunology, Laboratory of Robert Schreiber, PhD, Washington University School of Medicine, St. Louis, Missouri |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2019 - 2025
Parker Bridge Fellow, The Parker Institute for Cancer Immunotherapy (PICI), The University of Texas MD Anderson Cancer Center, Houston, Texas, 2019 - 2023
Research Instructor, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, 2017 - 2019
Other Professional Positions
Graduate Student Research Assistant, Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO, 2006 - 2012
Research Specialist, Department of Molecular Microbiology and Immunology, University of Missouri, Columbia, MO, 2005 - 2006
Intramural Institutional Committee Activities
Member, FY26 Executive Research Compliance Committee (ERCC), The University of Texas MD Anderson Cancer Center, 2026 - Present
Member, Research Integrity Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Graduate School of Biomedical Sciences Immunology Program Steering Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Extramural Institutional Committee Activities
Member, Stem Cell Transplantation Department Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2026 - Present
Member, SPORE in Hepatocellular Carcinoma Internal Advisory Board, The University of Texas MD Anderson Cancer Center, 2026 - Present
Member, MD Anderson/Johns Hopkins University Biliary Tract Cancers SPORE Advisory Board, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Department of Immunology Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Faculty Advisory Committee for Post-Doctoral Fellows in The MDACC Office of Mentoring and Training of Scientists, The University of Texas MD Anderson Cancer Center, 2021 - 2022
Faculty Advisor, CCIR-Immunology Trainee Seminar Series, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Junior Faculty Advisory Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2022
Editorial Activities
Invited participant, Springer Nature Editors Roundtable, Springer Nature/BMC, 2026
Deputy Editor, Nature Precision Oncology, 2025 - Present
Associate Editor, Nature Precision Oncology, 2020 - 2025
Honors & Awards
| 2026 - Present | Editorial Contribution Award 2026, Springer Nature |
| 2024 | Education and Mentorship Advancement Faculty Honoree, The University of Texas MD Anderson Cancer Center |
| 2022 | Andrew Sabin Family Fellow |
| 2022 | Leading Mentor in Cancer Prevention, Honorable Mention |
| 2021 | Arthur and Sandra Irving Scholar |
| 2011 | Clinical and Translational Research and Education Abstract Award, University of Missouri |
| 2011 | Institute for Clinical and Translational Science Travel Award (CTSA), National Center for Advancing Translational Sciences |
| 2010 | Life Science Week Research Competition Honorable Mention, University of Missouri Christopher S. Bond Life Sciences Center |
| 2010 | Missouri Superior Graduate Student Award, University of Missouri School of Medicine |
| 2010 | Professional Presentation Travel Fellowship, University of Missouri |
| 2009 | Chancellor's Award for Public Outreach, University of Missouri |
| 2008 | Missouri Health Science Research Day Award, University of Missouri School of Medicine |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Interrogation of Neoantigen-Specific T Cells Towards Improving Cancer Immunotherapy. Invited. Melanoma Research Seminar. Houston, Texas, US.
- 2023. Interrogation of Neoantigen-Specific T Cells Towards Improving Cancer Immunotherapy. Invited. Allison Institute Seminar Series. Houston, Texas, US.
- 2022. Interrogation of Neoantigen-Specific T Cells Towards Improving Cancer Immunotherapy. Invited. Cancer Center Support Grant & Molecular and Cellular Oncology Distinguished Scientist Seminar Series. Houston, Texas, US.
- 2021. From Research Technician to Assistant Professor and CPRIT Scholar: My Journey and What I've Learned. Invited. Career Development Seminar-Transition to Faculty: Reflections from CPRIT Scholars. Houston, Texas, US.
- 2021. Interrogation of Neoantigen-Specific T Cells Towards Improving Cancer Immunotherapy. Invited. MD Anderson Research Exchange Series. Houston, Texas, US.
- 2020. Interrogation of Neoantigen-Specific T Cells Towards Improving Cancer Immunotherapy. Invited. UT GSBS Immunology Program Faculty Seminar Series. Houston, Texas, US.
- 2018. Neoantigens and the Molecular Basis of Personalized Cancer Immunotherapy. Invited. Department of Immunology Seminar Series. Houston, Texas, US.
- 2016. Using Genomics to Define Cancer Immunoediting and Personalized Cancer Immunotherapy. Invited. Advanced Genomics Solution Symposium. St. Louis, MO, US.
- 2010. Overexpression of the RNA-Binding Protein HuR Impairs Tumor Growth in Estrogen Receptor Negative Breast Cancer Associated with Deficient Angiogenesis. Poster. Missouri Life Science Week. Columbia, MO, US.
- 2010. Coordinate Regulation of GATA3 and CD4+ T-helper 2 (TH2) Cytokine Gene Expression by the RNA-Binding Protein HuR. Poster. Missouri Health Sciences Research Day. Columbia, MO, US.
- 2009. Coordinate Posttranscriptional Regulation of Asthma Genes by the RNA Binding Protein HuR. Poster. Missouri Life Science Week. Columbia, MO, US.
- 2008. Posttranscriptional Gene Regulation in Breast Cancer: Role of RNA Binding Protein HuR. Poster. Missouri Health Science Research Day. Columbia, MO, US.
National Presentations
- 2024. Preclinical Model Approaches for Neoantigen Studies. Invited. Merck Neoantigen Prediction Approaches Scientific Input Engagement. San Francisco, California, US.
- 2022. T Cell Responses to Mutant Neoantigens and Non-Mutant Shared Antigens in a Cancer Vaccine Setting. Invited. 2022 Parker Institute for Cancer Immunotherapy Retreat. Healdsburg, CA, US.
- 2021. Interrogation of Neoantigen-Specific T Cells Towards Improving Cancer Immunotherapy. Invited. Department of Biology Seminar Series Saint Louis University. St. Louis, Missouri, US.
- 2021. Interrogation of Neoantigen-Specific T Cells Towards Improving Cancer Immunotherapy. Invited. Parker Institute for Cancer Immunotherapy Spring Retreat. Montecito, CA, US.
- 2020. Interrogation of Neoantigen-Specific T Cells Towards Improving Cancer Immunotherapy. Invited. Department of Molecular Microbiology and Immunology Seminar Series. St. Louis, Missouri, US.
- 2017. Remodeling of Intratumoral Myeloid and Lymphoid Compartments Following Immune Checkpoint Blockade Therapy. Invited. Immunotherapy Progress and Clinical Treatments. San Diego, CA, US.
- 2017. Remodeling of Intratumoral Myeloid and Lymphoid Compartments Following Immune Checkpoint Blockade Therapy. Invited. 32nd Annual Society for Immunotherapy of Cancer (SITC). National Harbor, MD, US.
- 2017. Immunotherapeutic Responses to Cancer Neoantigens. Invited. Frontiers in Cancer Immunotherapy. New York, NY, US.
- 2016. Immunotherapeutic Responses to Cancer Neoantigens. Invited. Chicago Illumina User Group Meeting. Chicago, IL, US.
- 2016. Immunotherapeutic Responses to Cancer Neoantigens. Invited. 3rd Annual Symposium on the Future of Cancer Science at MD Anderson Cancer Center. Houston, TX, US.
- 2011. Overexpression of the RNA-Binding Protein HuR Impairs Tumor Growth in Estrogen Receptor Negative Breast Cancer Associated with Deficient Angiogenesis. Poster. Breast Cancer Research Program (BCRP) Era of Hope Conference. Orlando, FL, US.
- 2011. Coordinate Regulation of GATA3 and Th2 Cytokine Gene Expression by the RNA-Binding Protein HuR. Invited. National Graduate Student Research Conference. Bethesda, MD, US.
- 2011. Overexpression of the RNA-Binding Protein HuR Impairs Tumor Growth in Estrogen Receptor Negative Breast Cancer Associated with Deficient Angiogenesis. Conference. 2011 Clinical and Translational Research and Education Meeting. Washington DC, US.
- 2010. RNA-Binding Protein HuR Coordinately Regulates Genes Essential for Th2 Polarization and Function at the Posttranscriptional Level. Conference. 97th American Association of Immunologists (AAI) Annual Meeting. Baltimore, MD, US.
- 2009. Coordinate Posttranscriptional Regulation of Asthma Genes by the RNA Binding Protein HuR. Conference. 96th American Association of Immunologists (AAI) Annual Meeting. Seattle, WA, US.
International Presentations
- 2026. Temporal evolution of the tumor immune microenvironment dictates combination requirements for effective immunotherapy. Conference. Cancer Immunology: Across Space and Time. Lisbon, PT.
- 2024. Overlapping and Distinct Mechanisms of Effective Neoantigen Vaccines and Immune Checkpoint Therapy. Invited. International Symposium on Cancer Immunology and Immunotherapy. Sapporo, JP.
- 2024. Overlapping and Distinct Mechanisms of Effective Neoantigen Vaccines and Immune Checkpoint Therapy. Invited. Keystone Symposia: Cancer Immunotherapy: Beyond Checkpoint Blockade and Overcoming Resistance. Whistler, CA.
- 2018. Neoantigens and the Molecular Basis of Personalized Cancer Immunotherapy. Invited. Moross Integrated Cancer Center (MICC) Symposium: From Cancer Genomics to Immunotherapy. Rehovot, IL.
- 2018. Neoantigens and the Molecular Basis of Personalized Cancer Immunotherapy. Invited. 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival. New York, US.
- 2017. Immunotherapeutic Responses to Cancer Neoantigens. Invited. 36th Sapporo International Cancer Symposium. Sapporo, JP.
- 2017. T Cell Responses to Tumor Neoantigens: Evidence for Dominant and Subdominant Neoepitopes. Conference. Keystone Symposia on Molecular and Cellular Biology: Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology. Whistler, CA.
- 2016. T Cell Responses to Tumor Neoantigens: Evidence for Dominant and Subdominant Neoepitopes. Invited. 2nd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival. New York, US.
- 2016. Tumor-Specific Mutant Antigens in Cancer Immunotherapy. Conference. Keystone Symposia on Molecular and Cellular Biology: Cancer Vaccines: Targeting Cancer Genes for Immunotherapy. Whistler, CA.
- 2015. Checkpoint Blockade Cancer Immunotherapy Targets Tumor-Specific Mutant Antigens. Conference. Keystone Symposia on Molecular and Cellular Biology: Tumor Immunology: Multidisciplinary Science Driving Combination Therapy. Banff, CA.
- 2015. Personalizing Cancer Immunotherapy. Invited. Cancer: Inflammation and Immunity Meeting, IT.
- 2014. Checkpoint Blockade Cancer Immunotherapy Targets Tumor-Specific Mutant Antigens. Conference. 22nd Annual International Cancer Immunotherapy Symposium. New York, US.
- 2014. Using Genomics to Identify Antigenic Targets of Checkpoint Blockade Therapy. Conference. Keystone Symposia on Molecular and Cellular Biology: Immune Evolution in Cancer. Whistler, CA.
- 2010. Overexpression of the RNA-Binding Protein HuR Impairs Tumor Growth in Estrogen Receptor Negative Breast Cancer Associated with Deficient Angiogenesis. Poster. 4th RNA Stability Meeting. Montreal, CA.
- 2010. Coordinate Regulation of GATA3 and CD4+ T-helper 2 (Th2) Cytokine Gene Expression by the RNA-Binding Protein HuR. Poster. 4th RNA Stability Meeting. Montreal, CA.
Grant & Contract Support
| Date: | 2027 - 2032 |
| Title: | The Texas Medical Center SPORE in Hepatocellular Carcinoma |
| Funding Source: | The National Institute of Health |
| Role: | IAB Member |
| ID: | FP00028990 |
| Date: | 2027 - 2032 |
| Title: | Redirecting Preexisting Antiviral Immunity Towards Cancer Immunotherapy |
| Funding Source: | National Cancer Institute |
| Role: | Co-PI |
| ID: | FP00030724 |
| Date: | 2027 - 2032 |
| Title: | Macrophage Fate Remodeling to Overcome Resistance to Cancer Immunotherapy |
| Funding Source: | NCI |
| Role: | Co-PI |
| ID: | 1 R01 CA 325521 - 01 |
| Date: | 2027 - 2030 |
| Title: | Targeting CXCL2 to Enhance Oncolytic Virotherapy |
| Funding Source: | DOD |
| Role: | PI |
| ID: | FP00031100 |
| Date: | 2027 - 2030 |
| Title: | Targeting CXCL2 to Enhance Oncolytic Virotherapy for Breast Cancer Brain Metastasis |
| Funding Source: | DOD |
| Role: | PI |
| ID: | FP00031355 |
| Date: | 2026 - 2031 |
| Title: | Mechanisms and Therapeutic Targeting of LOLXL2 in Melanoma Immunotherapy |
| Funding Source: | The National Institute of Health |
| Role: | Co-I |
| ID: | FP00029331 |
| Date: | 2026 - 2029 |
| Title: | Targeting Oncolysis-Induced Hypoxia to Improve Viro-Immunotherapy for Glioblastoma |
| Funding Source: | Cancer Prevention and Research Institute of Texas |
| Role: | Co-I |
| ID: | FP00030223 |
| Date: | 2026 - 2028 |
| Title: | Defining Bhlhe40 Regulation of Type 1 Conventional Dendritic Cell Function in Cancer Immunotherapy |
| Funding Source: | National Cancer Institute |
| Role: | PI |
| ID: | 1R21CA321523-01 |
| Date: | 2026 - 2029 |
| Title: | Developing Effective Cancer Vaccine-Based Combinatorial Therapies |
| Funding Source: | Cancer Prevention and Research Institute of Texas |
| Role: | PI |
| ID: | RP270606 |
| Date: | 2026 - 2029 |
| Title: | Targeting TREM-1 for Enhancing Viro-Immunotherapy for Glioblastoma |
| Funding Source: | US Department of Defense (DoD) (Subaward through University of Texas Health Science Center – Houston) |
| Role: | Co-I |
| ID: | FP00027880 |
| Date: | 2026 - 2031 |
| Title: | Targeting CXCL2 to Enhance Oncolytic Virotherapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | FP00026920 |
| Date: | 2026 - 2031 |
| Title: | Targeting CXCL2 to Enhance Oncolytic Virotherapy |
| Funding Source: | NCI (Subaward through University of Texas Health Science Center – Houston) |
| Role: | PI |
| ID: | FP00026727 |
| Date: | 2026 - 2030 |
| Title: | Spatiotemporal Mapping of Tumor Cell Death Rates During Immune Checkpoint Blockade to Identify Rate-limiting Steps in Response |
| Funding Source: | American Cancer Society, National (ACS) |
| Role: | PI |
| ID: | FP00026859 |
| Date: | 2026 - Present |
| Title: | Defining Cell-intrinsic vs. Cell-extrinsic Mechanisms Driving Protective Anti-tumor Immunity Downstream of PD-1 Checkpoint Inhibition |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | 1 R01 CA 310892 - 01 |
| Date: | 2026 - 2029 |
| Title: | Reprogramming Glioblastoma Tumor Microenvironment by Triple Cell Targeting with Multifunctional MicroRNAs |
| Funding Source: | American Cancer Society (ACS) (Subaward through University of Texas Health Science Center – Houston) |
| Role: | PI |
| ID: | FP00026725 |
| Date: | 2025 - 2030 |
| Title: | Targeting Macrophage and T Cell Networks to Enhance Cancer Immunotherapy |
| Funding Source: | NIH |
| Role: | Co-PI |
| ID: | 1 R01 CA 314062 - 01 |
| Date: | 2025 - 2028 |
| Title: | Spatiotemporal Mapping of Tumor Cell Death Rates During Immune Checkpoint Blockade to Identify Rate-limiting Steps in Response |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP260447 |
| Date: | 2025 - 2030 |
| Title: | Triple Cell Targeting with Multifunctional MicroRNAs for Reprogramming Glioblastoma Tumor Microenvironment |
| Funding Source: | NIH/NCI (Subaward through University of Texas Health Science Center – Houston) |
| Role: | Co-I |
| ID: | FP00025318 |
| Date: | 2025 - 2030 |
| Title: | Developing Effective Cancer Vaccine-Based Combinatorial Therapies |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 1R01CA291917-01A1 |
| Date: | 2025 - 2028 |
| Title: | Developing Effective Cancer Vaccine-Based Combinatorial Therapies |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| ID: | RP260524 |
| Date: | 2025 - 2028 |
| Title: | Sensitizing Glioblastoma to Oncolytic Viruses through Targeted MicroRNA Modulation |
| Funding Source: | NCI (Sub-award through University of Texas Health Science Center – Houston) |
| Role: | Co-I |
| ID: | FP00026175 |
| Date: | 2025 - 2027 |
| Title: | Remodeling Myeloid Immunosuppression and Defining Spatial Biomarkers to Improve Neoantigen Cancer Vaccine Efficacy |
| Funding Source: | American Cancer Society - Yosemite |
| Role: | PI |
| ID: | FP00026852 |
| Date: | 2025 - 2028 |
| Title: | Evaluating Antigen Spread After cDC1 Vaccination |
| Funding Source: | NIH/NCI |
| Role: | Other Significant Contributor |
| ID: | 1F30CA290816-01A1 |
| Date: | 2025 - 2030 |
| Title: | Sensitizing Glioblastoma to Oncolytic Viruses through Targeted MicroRNA Modulation |
| Funding Source: | NIH/NCI (Subaward through University of Texas Health Science Center – Houston) |
| Role: | Co-I |
| ID: | FP00024605 |
| Date: | 2025 - 2030 |
| Title: | Harnessing Oncolytic Viro-therapy |
| Funding Source: | NIH/NCI (Subaward through University of Texas Health Science Center – Houston |
| Role: | Co-I |
| ID: | FP00019749_Res1 |
| Date: | 2025 - 2030 |
| Title: | Harnessing Leukocyte Recruitment to Enhance PD-1-based Immunotherapy for Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA302939-01 |
| Date: | 2025 - 2028 |
| Title: | Mechanistic Basis of Novel Neoantigen Vaccine-Based Combination Therapies |
| Funding Source: | Melanoma Research Alliance (MRA) |
| Role: | PI |
| ID: | FP00024685 |
| Date: | 2025 - 2028 |
| Title: | Developing Effective Cancer Vaccine-Based Combinatorial Therapies |
| Funding Source: | CPRIT |
| Role: | PI |
| ID: | RP250200 |
| Date: | 2024 - 2025 |
| Title: | Elucidating the Role of MHC-I and MHC-II Tumor Antigen Presentation by Migratory Type 1 Conventional Dendritic Cell Vaccines |
| Funding Source: | Janssen Research and Development |
| Role: | Mentor |
| ID: | FP00025067; Fund: 00017400 |
| Date: | 2024 - 2029 |
| Title: | Developing Effective Cancer Vaccine-Based Combinatorial Therapies |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | CA291917-01 |
| Date: | 2024 - 2029 |
| Title: | Bhlhe40 Regulation of T Cell Function During Cancer Immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA282027-01A1 |
| Date: | 2024 - 2024 |
| Title: | Mechanisms of Dendritic Cell Melanoma Vaccines Towards Improved Efficacy |
| Funding Source: | The University of Texas MD Anderson Cancer Center – Melanoma SPORE DRP |
| Role: | PI |
| ID: | 2023-00062938-Y1; Fund: 128861 |
| Date: | 2023 - 2028 |
| Title: | Enhanced Viro-Immunotherapy for Breast Cancer Brain Metastasis |
| Funding Source: | NCI (Subaward through University of Texas Health Science Center – Houston) |
| Role: | Co-I |
| ID: | 5R01CA276942-02 |
| Date: | 2023 - 2028 |
| Title: | Remodeling the Tumor and the Immune Microenvironment to Eliminate Therapy-Resistant Triple-Negative Breast Cancers (TNBCs) |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator, Core 3 and Project 3 |
| ID: | 1P01CA275720-01A1 |
| Date: | 2022 - 2024 |
| Title: | Overcoming Immunotherapy Resistance in Tumors Lacking Strong MHC-I or MHC-II Neoantigens |
| Funding Source: | Sabin Family Foundation |
| Role: | PI |
| Date: | 2022 - 2024 |
| Title: | IGF1R-Targeted Oncolytic Herpes Simplex Viral Therapy for Glioblastoma |
| Funding Source: | NINDS (Subaward through University of Texas Health Science Center – Houston) |
| Role: | Co-I |
| ID: | 1R21NS123685-01A1 |
| Date: | 2021 - 2026 |
| Title: | Remodeling the Tumor and the Immune Microenvironment to Impact Chemoresistant Triple-Negative Breast Cancers (TNBCs) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1P01CA257916-01A1 |
| Date: | 2021 - 2026 |
| Title: | Exercise Modulation of ERK5 as a Novel Method of Vascular Remodeling in Melanoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA266525-01 |
| Date: | 2021 - 2026 |
| Title: | Comprehensive Epigenomic Characterization of T Cell Differentiation and Tissue Residency at Single Cell Resolution |
| Funding Source: | NIH/NHGRI |
| Role: | Co-I |
| ID: | 1UM1HG012026-01 |
| Date: | 2021 - 2026 |
| Title: | Characterization of Functional Regulatory Elements During T-Cell Differentiation |
| Funding Source: | NIH/NHGRI |
| Role: | Co-I |
| ID: | 1UM1HG012063-01 |
| Date: | 2021 - 2026 |
| Title: | Targeting Tankyrase to Destabilize Programmed Death Ligand-1 for Immune Stimulation and Enhance Cancer Immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA258583-01 |
| Date: | 2020 - 2025 |
| Title: | Understanding and Targeting the Defective Immune Landscape in Colon Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA251224-01 |
| Date: | 2020 - 2022 |
| Title: | Investigating IL-15's Ability to Shape the Metabolic Landscape in Colon Carcinoma Tumors |
| Funding Source: | NIH/NCI |
| Role: | Other Significant Contributor |
| ID: | 1R21CA249037-01 |
| Date: | 2019 - 2022 |
| Title: | Bridge Scholar Award: Therapeutic Responses to Tumor-Specific Neoantigens in Metastatic Mouse Cancer Models |
| Funding Source: | Parker Institute for Cancer Immunotherapy (PICI) |
| Role: | PI |
| Date: | 2019 - 2021 |
| Title: | New Faculty Award |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 2P30CA016672-43 |
| Date: | 2019 - 2022 |
| Title: | UT System Rising STARs Award |
| Funding Source: | The University of Texas System |
| Role: | PI |
| Date: | 2018 - 2024 |
| Title: | Therapeutic Responses to Tumor-Specific Neoantigens in Primary and Metastatic Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RR190017 |
| Date: | 2014 - 2017 |
| Title: | Cancer Research Institute (CRI) Postdoctoral Fellowship Program – Using Genomics to Identify Targets of Checkpoint Blockade Cancer Therapy and to Identify Optimal Target Antigens for Vaccination |
| Funding Source: | Cancer Research Institute (CRI) |
| Role: | PI |
| Date: | 2012 - 2014 |
| Title: | Institutional Research Training Grant |
| Funding Source: | Ruth L. Kirschstein National Research Service Award (NRSA) |
| Role: | Trainee |
Selected Publications
Peer-Reviewed Articles
- Pineda JE, Minowa T, Shen L, Zhou Y, Dyevoich A, Patel B, Schneider SM, Keshari S, Saha A, Riba MN, Wang J, Watowich SS, Gubin MM. Antigen presentation requirements for effective cDC1-based cancer immunotherapy. J Immunol 215(8), 2026. e-Pub 2026. PMID: 42592936.
- Egbulefu C, Black K, Su X, Karmakar P, Habimana-Griffin L, Sudlow G, Prior J, Onejeme E, Zheleznyak A, Xu B, Xu Y, Esser A, Mixdorf M, Moss E, Manion B, Hongsermeier C, Gamadia N, Blasi N, Stallings L, Alagbaoso C, Reed N, Gubin MM, Lin C, Schreiber R, Weilbaecher K, Achilefu S. Radionuclide-stimulated dynamic therapy induces complementary immunogenic necroptosis and apoptosis cancer cell death pathways. Communications Biology 9(1), 2026. e-Pub 2026. PMID: 41554980.
- He S, Tan Y, Ye Q, Gubin MM, Rafei H, Peng W, Rezvani K, Mohanty V, Chen K. AI-powered Immune Cell Knowledge Graph (ICKG) with granular immune contexts enables immune program interpretation. npj Artificial Intelligence 2(1), 2026. e-Pub 2026. PMID: 41614120.
- Chaib M, Aminu M, Herbrich S, Arabi M, Xuan Y, Basi A, Casasent A, Macaluso MD, Hu KH, Gubin M, Chen X, Mancuso JJ, Basu S, Jindal S, Burks J, Watowich S, Wu J, Allison JP, Sharma P. Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade. bioRxiv, 2025. PMID: 41509466.
- Saha A, Minowa T, Shavkunov AS, Salmon AJ, Keshari S, Jarjour NN, Pauken KE, Hu KH, Edelson BT, Chen K, Gubin MM. Bhlhe40 Coordinates T Cell Programs with Distinct CD4 and CD8 T Cell Requirements for Anti-PD-1 Versus Anti-CTLA-4. bioRxiv, 2025. PMID: 41279383.
- He S, Tan Y, Ye Q, Gubin M, Rafei H, Peng W, Rezvani K, Mohanty V, Chen K. Literature-scaled immunological gene set annotation using AI-powered immune cell knowledge graph (ICKG). bioRxiv, 2025. PMID: 40060525.
- Keshari S, Shavkunov AS, Miao Q, Saha A, Minowa T, Molgora M, Williams CD, Chaib M, Highsmith AM, Pineda JE, Alekseev S, Alspach E, Hu KH, Colonna M, Pauken KE, Chen K, Gubin MM. Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy. Cell Rep 43(11):114875, 2024. e-Pub 2024. PMID: 39446585.
- He S, Gubin MM, Rafei H, Basar R, Dede M, Jiang X, Liang Q, Tan Y, Kim K, Gillison ML, Rezvani K, Peng W, Haymaker C, Hernandez S, Solis LM, Mohanty V, Chen K. Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profiles. iScience 27(6):110096, 2024. e-Pub 2024. PMID: 38957791.
- He S, Gubin MM, Rafei H, Basar R, Dede M, Jiang X, Liang Q, Tan Y, Kim K, Gillison ML, Rezvani K, Peng W, Haymaker C, Hernandez S, Solis LM, Mohanty V, Chen K. Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profiles. bioRxiv, 2024. PMID: 38798470.
- Keshari S, Shavkunov AS, Miao Q, Saha A, Williams CD, Highsmith AM, Pineda JE, Alspach E, Hu KH, Pauken KE, Chen K, Gubin MM. Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy. bioRxiv, 2024. e-Pub 2024. PMID: 38187708.
- He M, Roussak K, Ma F, Borcherding N, Garin V, White M, Schutt C, Jensen TI, Zhao Y, Iberg CA, Shah K, Bhatia H, Korenfeld D, Dinkel S, Gray J, Ulezko Antonova A, Ferris S, Donermeyer D, Lindestam Arlehamn C, Gubin MM, Luo J, Gorvel L, Pellegrini M, Sette A, Tung T, Bak R, Modlin RL, Fields RC, Schreiber RD, Allen PM, Klechevsky E. CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses. Science 379(6633):eabg2752, 2023. e-Pub 2023. PMID: 36795805.
- Zhou Y, Medik YB, Patel B, Zamler DB, Chen S, Chapman T, Schneider S, Park EM, Babcock RL, Chrisikos TT, Kahn LM, Dyevoich AM, Pineda JE, Wong MC, Mishra AK, Cass SH, Cogdill AP, Johnson DH, Johnson SB, Wani K, Ledesma DA, Hudgens CW, Wang J, Wadud Khan MA, Peterson CB, Joon AY, Peng W, Li HS, Arora R, Tang X, Raso MG, Zhang X, Foo WC, Tetzlaff MT, Diehl GE, Clise-Dwyer K, Whitley EM, Gubin MM, Allison JP, Hwu P, Ajami NJ, Diab A, Wargo JA, Watowich SS. Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration. J Exp Med 220(2):e20221333, 2023. e-Pub 2023. PMID: 36367776.
- Hsieh RC, Krishnan S, Wu RC, Boda AR, Liu A, Winkler M, Hsu WH, Lin SH, Hung MC, Chan LC, Bhanu KR, Srinivasamani A, De Azevedo RA, Chou YC, DePinho RA, Gubin M, Vilar E, Chen CH, Slay R, Jayaprakash P, Hegde SM, Hartley G, Lea ST, Prasad R, Morrow B, Couillault CA, Steiner M, Wang CC, Venkatesulu BP, Taniguchi C, Kim YSB, Chen J, Rudqvist NP, Curran MA. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Sci Immunol 7(72):eabl9330, 2022. e-Pub 2022. PMID: 35687697.
- Salmon AJ, Shavkunov AS, Miao Q, Jarjour NN, Keshari S, Esaulova E, Williams CD, Ward JP, Highsmith AM, Pineda JE, Taneja R, Chen K, Edelson BT, Gubin MM. BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy. Cancer Immunol Res 10(5):597-611, 2022. e-Pub 2022. PMID: 35181783.
- Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, Brioschi S, Bugatti M, Omodei AS, Ricci B, Fronick C, Panda SK, Takeuchi Y, Gubin MM, Faccio R, Cella M, Gilfillan S, Unanue ER, Artyomov MN, Schreiber RD, Colonna M. TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy. Cell 182(4):886-900.e17, 2020. e-Pub 2020. PMID: 32783918.
- Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, Meng W, Lichti CF, Esaulova E, Vomund AN, Runci D, Ward JP, Gubin MM, Medrano RFV, Arthur CD, White JM, Sheehan KCF, Chen A, Wucherpfennig KW, Jacks T, Unanue ER, Artyomov MN, Schreiber RD. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574(7780):696-701, 2019. e-Pub 2019. PMID: 31645760.
- Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, Medrano RFV, Fronick C, Fehlings M, Newell EW, Fulton RS, Sheehan KCF, Oh ST, Schreiber RD, Artyomov MN. High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. Cell 175(4):1014-1030.e19, 2018. e-Pub 2018. PMID: 30343900.
- Fehlings M, Simoni Y, Penny HL, Becht E, Loh CY, Gubin MM, Ward JP, Wong SC, Schreiber RD, Newell EW. Author Correction: Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells. Nat Commun 9(1):3000, 2018. e-Pub 2018. PMID: 30050138.
- Fehlings M, Simoni Y, Penny HL, Becht E, Loh CY, Gubin MM, Ward JP, Wong SC, Schreiber RD, Newell EW. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells. Nat Commun 8(1):562, 2017. e-Pub 2017. PMID: 28916749.
- Techasintana P, Ellis JS, Glascock J, Gubin MM, Ridenhour SE, Magee JD, Hart ML, Yao P, Zhou H, Whitney MS, Franklin CL, Martindale JL, Gorospe M, Davis WJ, Fox PL, Li X, Atasoy U. The RNA-Binding Protein HuR Posttranscriptionally Regulates IL-2 Homeostasis and CD4+ Th2 Differentiation. Immunohorizons 1(6):109-123, 2017. e-Pub 2017. PMID: 30035254.
- Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, Selby MJ, Graziano RF, Mardis ER, Korman AJ, Schreiber RD. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. Cancer Immunol Res 5(2):106-117, 2017. e-Pub 2017. PMID: 28073774.
- Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, Tonc E, Schreiber RD, Pearce EJ, Pearce EL. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell 162(6):1229-41, 2015. e-Pub 2015. PMID: 26321679.
- Techasintana P, Davis JW, Gubin MM, Magee JD, Atasoy U. Transcriptomic-Wide Discovery of Direct and Indirect HuR RNA Targets in Activated CD4+ T Cells. PLoS One 10(7):e0129321, 2015. e-Pub 2015. PMID: 26162078.
- Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515(7528):577-81, 2014. e-Pub 2014. PMID: 25428507.
- Gubin MM, Techasintana P, Magee JD, Dahm GM, Calaluce R, Martindale JL, Whitney MS, Franklin CL, Besch-Williford C, Hollingsworth JW, Abdelmohsen K, Gorospe M, Atasoy U. Conditional knockout of the RNA-binding protein HuR in CD4? T cells reveals a gene dosage effect on cytokine production. Mol Med 20:93-108, 2014. e-Pub 2014. PMID: 24477678.
- Chen J, Cascio J, Magee JD, Techasintana P, Gubin MM, Dahm GM, Calaluce R, Yu S, Atasoy U. Posttranscriptional gene regulation of IL-17 by the RNA-binding protein HuR is required for initiation of experimental autoimmune encephalomyelitis. J Immunol 191(11):5441-50, 2013. e-Pub 2013. PMID: 24166976.
- Calaluce R, Davis JW, Bachman SL, Gubin MM, Brown JA, Magee JD, Loy TS, Ramshaw BJ, Atasoy U. Incisional hernia recurrence through genomic profiling: a pilot study. Hernia 17(2):193-202, 2013. e-Pub 2013. PMID: 22648066.
- Dahm GM, Gubin MM, Magee JD, Techasintana P, Calaluce R, Atasoy U. Method for the isolation and identification of mRNAs, microRNAs and protein components of ribonucleoprotein complexes from cell extracts using RIP-Chip. J Vis Exp(67), 2012. e-Pub 2012. PMID: 23051702.
- Stellato C, Gubin MM, Magee JD, Fang X, Fan J, Tartar DM, Chen J, Dahm GM, Calaluce R, Mori F, Jackson GA, Casolaro V, Franklin CL, Atasoy U. Coordinate regulation of GATA-3 and Th2 cytokine gene expression by the RNA-binding protein HuR. J Immunol 187(1):441-9, 2011. e-Pub 2011. PMID: 21613615.
- Gubin MM, Calaluce R, Davis JW, Magee JD, Strouse CS, Shaw DP, Ma L, Brown A, Hoffman T, Rold TL, Atasoy U. Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis. Cell Cycle 9(16):3337-46, 2010. e-Pub 2010. PMID: 20724828.
- Calaluce R, Gubin MM, Davis JW, Magee JD, Chen J, Kuwano Y, Gorospe M, Atasoy U. The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer. BMC Cancer 10:126, 2010. e-Pub 2010. PMID: 20370918.
Invited Articles
- Gubin MM. Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology Keystone Symposia Meeting Summary. Cancer Immunol Res 5(6):434-438, 2017. e-Pub 2017. PMID: 28576922.
- Gubin MM, Schreiber RD. CANCER. The odds of immunotherapy success. Science 350(6257):158-9, 2015. e-Pub 2015. PMID: 26450194.
Review Articles
- Minowa T, Murata K, Watowich SS, Gubin MM, Hirohashi Y. Immune microenvironment and strategy of immunotherapy in acral melanoma. Immunol Med, 2026. PMID: 42118977.
- Gubin MM, Vesely MD. Cancer Immunoediting in the Era of Immuno-oncology. Clin Cancer Res 28(18):3917-3928, 2022. e-Pub 2022. PMID: 35594163.
- Ward JP, Gubin MM, Schreiber RD. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. Adv Immunol 130:25-74, 2016. e-Pub 2016. PMID: 26922999.
- Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest 125(9):3413-21, 2015. e-Pub 2015. PMID: 26258412.
- Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol 27:16-25, 2014. e-Pub 2014. PMID: 24531241.
Other Articles
- Shavkunov AS, Gubin MM The dynamics of an immunotherapy duo. Nat Cancer 3(4):376-378, 2022. PMID: 35484417.
- Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, Medrano RFV, Fronick C, Fehlings M, Newell EW, Fulton RS, Sheehan KCF, Oh ST, Schreiber RD, Artyomov MN High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. Cell 175(5):1443, 2018. PMID: 30445041.
Book Chapters
- Ward JP, Gubin MM, Schreiber RD. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. In: Advances in Immunology. Chapter 2, 25-74, 2016.
Patient Reviews
CV information above last modified September 04, 2026